Suchen Sie nach Informationen zu Fluidigma-Hauptsitz? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
https://www.fluidigm.com/about/contactus/locations
Corporate headquarters. 2 Tower Place, Suite 2000 South San Francisco, CA 94080. T: 650 266 6000 F: 650 871 7152 Toll free: 866 359 4354
https://www.fluidigm.com/about/contactus
Interested in Standard BioTools products or need a quote? Talk to the sales team in your region.
https://www.fluidigm.com/
Our mission is to provide you with the right, reliable products to solve your problems. Introducing Standard BioTools™. A company and a name that reflect our commitment to you, the researcher and inventor: To unleash the power of essential, standardized tools that help the life science industry. develop breakthrough medicines faster and better.
https://www.fluidigm.com/MOD
Maxpar OnDemand antibodies come in fixed 15 µg (0.5 mg/mL) vials and ship within 6 business days. They can be ordered in the same way as any of our catalog products. For a list of currently available Maxpar OnDemand Antibodies, download the TDS here. Mouse formalin-fixed, paraffin-embedded (FFPE) prostate positive control tissue stained with ...
https://investors.fluidigm.com/
About the Company. Standard BioTools (Nasdaq: LAB), previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better.
https://investors.fluidigm.com/news-releases/news-release-details/fluidigm-announces-fourth-quarter-and-full-year-2021-financial
Fourth Quarter 2021 Financial Results. Total revenue was $38.3 million for the quarter ended December 31, 2021, compared with $44.6 million for the fourth quarter of 2020. Base product and service revenue (excluding COVID-19 testing revenue) increased 13.5 percent to $35.3 million, compared with $31.1 million in the same period last year.
https://investors.fluidigm.com/news-releases/news-release-details/fluidigm-announces-first-quarter-2021-financial-results-total
Forecasting underlying base business growth of 16–17% supported by new product innovation. SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the first …
https://investors.fluidigm.com/news-releases/news-release-details/fluidigm-stockholders-approve-250-million-strategic-capital
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”).
https://go.fluidigm.com/SIgN-Fluidigm_SpatialResearchAward2022
Program Scope: This award will cover sample-to-solution IMC services including slide staining, data acquisition and single-cell data analysis. The awarded research will be given a chance to submit samples for immune staining using the Maxpar® Human Immuno-Oncology IMC Panel Kit (18-plex) with segmentation markers and for imaging on the Hyperion™ Imaging System, …
https://investors.fluidigm.com/press-releases
Capacity to Process 100-Plus Samples per Week, with 1.6x Lower Limit of Detection SOUTH SAN FRANCISCO, Calif. , April 11, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced the
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Fluidigma-Hauptsitz gefunden haben.
